PLEGRIDY KIT

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

PEGINTERFERON BETA-1A; PEGINTERFERON BETA-1A

Saadav alates:

BIOGEN CANADA INC

ATC kood:

L03AB13

INN (Rahvusvaheline Nimetus):

PEGINTERFERON BETA-1A

Annus:

63MCG; 94MCG

Ravimvorm:

KIT

Koostis:

PEGINTERFERON BETA-1A 63MCG; PEGINTERFERON BETA-1A 94MCG

Manustamisviis:

SUBCUTANEOUS

Ühikuid pakis:

0.5ML SYRINGE OR PEN AND 0.5 ML SYRINGE OR PEN

Retsepti tüüp:

Prescription

Terapeutiline ala:

INTERFERONS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0257231001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2015-08-10

Toote omadused

_PLEGRIDY_
_TM_
_ (peginterferon beta-1a) _
_Page 1 of 47 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PLEGRIDY
TM
peginterferon beta-1a
Liquid for injection
Immunomodulator
Biogen Canada Inc.
3250 Bloor Street West, East Tower, Suite 1200
Toronto, ON
M8X 2X9
Date of Initial Authorization:
August 10, 2015
Date of Revision:
June 26, 2023
Submission Control Number: 271667
© Biogen [2015]. All rights reserved.
_ _
_ _
_PLEGRIDY_
_TM_
_ (peginterferon beta-1a) _
_Page 2 of 47_
RECENT MAJOR LABEL CHANGES
7.1.1 Pregnant Women
05/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
4
4.1
Dosing Considerations
.......................................................................................
4
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.4
Administration...................................................................................................
6
4.5
Missed Dose
..............................................................